Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Mol Graph Model ; 84: 125-133, 2018 09.
Article in English | MEDLINE | ID: mdl-29960255

ABSTRACT

Increasing resistance against available orthosteric beta-lactamase inhibitors necessitates the search for novel and powerful inhibitor molecules. In this respect, allosteric inhibitors serve as attractive alternatives. Here, we examine the structural basis of inhibition in a hidden, druggable pocket in TEM-1 beta-lactamase. Based on crystallographic evidence that 6-cyclohexyl-1-hexyl-ß-D-maltoside (CYMAL-6) binds to this site, first we determined the kinetic mechanism of inhibition by CYMAL-6. Activity measurements with CYMAL-6 showed that it competitively inhibits the wild type enzyme. Interestingly, it exhibits a steep dose-response curve with an IC50 of 100 µM. The IC50 value changes neither with different enzyme concentration nor with incubation of the enzyme with the inhibitor, showing that inhibition is not aggregation-based. The presence of the same concentrations of CYMAL-6 does not influence the activity of lactate dehydrogenase, further confirming the specificity of CYMAL-6 for TEM-1 beta-lactamase. Then, we identified compounds with high affinity to this allosteric site by virtual screening using Glide and Schrödinger Suite. Virtual screening performed with 500,000 drug like compounds from the ZINC database showed that top scoring compounds interact with the hydrophobic pocket that forms between H10 and H11 helices and with the catalytically important Arg244 residue through pi-cation interactions. Discovery of novel chemical scaffolds that target this allosteric site will pave the way for a new avenue in the design of new antimicrobials.


Subject(s)
Molecular Docking Simulation , Molecular Dynamics Simulation , beta-Lactamase Inhibitors/chemistry , beta-Lactamases/chemistry , Allosteric Site/drug effects , Binding Sites , Hydrolysis , Kinetics , L-Lactate Dehydrogenase/chemistry , Protein Binding , beta-Lactamase Inhibitors/pharmacology
2.
Curr Genet ; 63(4): 709-722, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28013396

ABSTRACT

Among the different families of plant alkaloids, (-)-roemerine, an aporphine type, was recently shown to possess significant antibacterial activity in Escherichia coli. Based on the increasing demand for antibacterials with novel mechanisms of action, the present work investigates the potential of the plant-derived alkaloid (-)-roemerine as an antibacterial in E. coli cells using microarray technology. Analysis of the genome-wide transcriptional reprogramming in cells after 60 min treatment with 100 µg/mL (-)-roemerine showed significant changes in the expression of 241 genes (p value <0.05 and fold change >2). Expression of selected genes was confirmed by qPCR. Differentially expressed genes were classified into functional categories to map biological processes and molecular pathways involved. Cellular activities with roles in carbohydrate transport and metabolism, energy production and conversion, lipid transport and metabolism, amino acid transport and metabolism, two-component signaling systems, and cell motility (in particular, the flagellar organization and motility) were among metabolic processes altered in the presence of (-)-roemerine. The down-regulation of the outer membrane proteins probably led to a decrease in carbohydrate uptake rate, which in turn results in nutrient limitation. Consequently, energy metabolism is slowed down. Interestingly, the majority of the expressional alterations were found in the flagellar system. This suggested reduction in motility and loss in the ability to form biofilms, thus affecting protection of E. coli against host cell defense mechanisms. In summary, our findings suggest that the antimicrobial action of (-)-roemerine in E. coli is linked to disturbances in motility and nutrient uptake.


Subject(s)
Alkaloids/pharmacology , Biofilms/drug effects , Cell Movement/drug effects , Escherichia coli/drug effects , Alkaloids/chemistry , Anti-Bacterial Agents/pharmacology , Biofilms/growth & development , Biological Transport/drug effects , Biological Transport/genetics , Energy Metabolism/drug effects , Escherichia coli/genetics , Escherichia coli/pathogenicity , Escherichia coli Infections/drug therapy , Escherichia coli Infections/genetics , Escherichia coli Infections/microbiology , Gene Expression Profiling , Gene Expression Regulation, Bacterial/drug effects , Humans
3.
J Enzyme Inhib Med Chem ; 31(sup3): 33-40, 2016.
Article in English | MEDLINE | ID: mdl-27353461

ABSTRACT

Declining efficiency of antibiotic-inhibitor combinatorial therapies in treating beta-lactamase mediated resistance necessitates novel inhibitor development. Allosteric inhibition offers an alternative to conventional drugs that target the conserved active site. Here, we show that the evolutionarily conserved PWP triad located at the N-terminus of the H10 helix directly interacts with the allosteric site in TEM-1 beta-lactamase and regulates its activity. While point mutations in the PWP triad preserve the overall secondary structures around the allosteric site, they result in a more open and dynamic global structure with decreased chemical stability and increased aggregation propensity. These mutant enzymes with a less compact hydrophobic core around the allosteric site displayed significant activity loss. Detailed sequence and structure conservation analyses revealed that the PWP triad is an evolutionarily conserved motif unique to class A beta-lactamases aligning its allosteric site and hence is an effective potential target for enzyme regulation and selective drug design.


Subject(s)
Allosteric Site , Conserved Sequence , Evolution, Molecular , beta-Lactamases/chemistry , beta-Lactamases/metabolism , Allosteric Site/drug effects , Amino Acid Motifs , Drug Design , Enzyme Activation/drug effects , Models, Molecular , Point Mutation , Urea/pharmacology , beta-Lactamases/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...